Skip to content

B.K. PHARMA

Active Private limited companyfounded 2011active for 15 yearsWayezstraat 48, 1070 AnderlechtKBO/BCE: BE 0834.173.472

Lifetime

15 annual accounts with figures on one time axis
peak of €206,575 in 2017
€112,702▼ 25.5%
lowest -€51,519 in 2011
€26,588▼ 54.4%
peak of €192,565 in 2025
€192,565▲ 16.0%
€228,911▼ 19.7%
peak of 1 FTE in 2021
-not published
Board10 names since 2011
1 director
Documentsfilings and deeds
28-08-202628 days late
2025micro format
Gross margin from €151,230 to €112,702Result from €58,298 to €26,588Equity from €165,977 to €192,565Debts from €285,003 to €228,911Cash from €123,290 to €78,043

Key points

from the 2025 annual accounts

Equity

€192,565 ▲ 16.0%

B.K. PHARMA has made a profit without a break since 2014.

Turnover

≈ €390,000 estimated

The accounts state no turnover.

Filings

15 annual accounts since 2011
AprilJune31 JulyOctober201520202025

Six of the last ten came late. The 2021 accounts came in latest, 61 days after the end of the period.

Checked score

Bankruptcy probability within 12 months

Financial strength

Score breakdown

Comparable companies, two years later

In July 2024, 34,726 companies had the same profile as B.K. PHARMA has now. Each dot stands for 87 companies, two years later.

95.2%
were still trading
4.0%
stopped another way
0.7%
went bankrupt
  • Micro
  • 10 to 20 years old
  • solvency 30% or more
  • a profit of 5% of the balance sheet or more
Test of the method

The method was tested on the 497,965 companies of July 2024. Each company was given the bankruptcy share of the same profile a year earlier, in July 2023. The expectation was that 1.6% would go bankrupt within 24 months. In fact 1.7% went bankrupt.

The companies in ten equal groups, from the lowest to the highest expected share
Group Expected Actual
1 0.2% 0.2%
2 0.3% 0.5%
3 0.5% 0.6%
4 0.7% 0.8%
5 0.9% 0.9%
6 1.3% 1.5%
7 1.6% 1.8%
8 1.8% 1.8%
9 2.9% 3.1%
10 5.6% 6.1%

A company that went bankrupt had a higher expected share than one that kept going in 74.5% of comparisons. The level depends on the economy. In a year with more bankruptcies than the year before, the actual share is higher than the expected one.

This is an observation about 34,726 companies, not a prediction for B.K. PHARMA. The sector does not count, because the KBO no longer lists a sector for a company that has stopped. By sector, mostly the survivors would count, which would paint too rosy a picture.

Credit verdict

Credit check for an amount and term of your choice

Show the recommended maximum and see how the verdict changes with amount, term and advance.

The scores and ratios are Checked's own calculations, not a credit decision.

Signals

Board and ownership

Director
  • 100 sharesdeed of 27-02-2014
Board & ownership

Recent changes

Registered in the Peppol Directory Reachable for e-invoices through 0208:0834173472
Amendment of the articles · Legal-form change · Resignations & appointments is in office as director · is in office as director · Gazette deed
appointed as mandate holder General meeting of 01-04-2023 · Gazette deed
resigns as director Discharge granted to · General meeting of 31-08-2020 · Gazette deed
All 35 events

Comparable companies

same main activity, similar in size and age
Company
B.K. PHARMA Anderlecht €421,476 €112,702 45.7% -
PHARMACIE DE MAET Ganshoren €444,040 €114,557 74.2% -
PHARMACIE GILISQUET Schaerbeek €391,819 €117,002 -80.8% -
BIOMEDIM Plombières €430,148 €110,061 86.7% -
PHARMACIE DUTRON Charleroi €431,827 €106,983 70.0% -
PHARMACAM Kraainem €410,625 €118,350 67.9% -
Apotheek Katleen Vantieghem Zwevegem €430,931 €101,567 43.3% 0.2

These companies have the same main activity as B.K. PHARMA: retail sale of pharmaceutical products (NACE 47730). They are comparable in size and age: total assets between €392,000 and €444,000, founded between 2009 and 2012.

Official details

Source: KBO
Status
Active since 01-03-2011Normal situation
Activity
Retail sale of pharmaceutical productsNACE 47730
Establishment unit
2.197.133.9341070 Anderlecht, since 03-03-2011
Financial year end
31 December
Peppol
Reachable since 17-12-2025
Company details

Annual accounts 2025

€421,476▼ 6.5%
Employeeson 31-12-2025
1=
Filing
Filed on 28-08-2026
Financials

Insights on B.K. PHARMA

B.K. PHARMA files the micro format. That format states no turnover. The gross margin rose from €43,287 in 2011 to €112,702 in 2025.

The balance sheet grew most from 2012 to 2013 through fixed assets, financed with long-term debt.

Sources: KBO register, filings at the National Bank, Belgian Official Gazette. Click a figure with a dotted line for the item and the filing.

Key facts about B.K. PHARMA

What is the company number of B.K. PHARMA?
The company number of B.K. PHARMA is 0834.173.472. The VAT number is the same number with BE in front: BE 0834.173.472.
Where is B.K. PHARMA based?
The registered office is at Wayezstraat 48, 1070 Anderlecht.Company details
What does B.K. PHARMA do?
According to the KBO register, the main activity is retail sale of pharmaceutical products (NACE 47730).
What is the legal form of B.K. PHARMA?
B.K. PHARMA is a private limited company (BV).
When was B.K. PHARMA founded?
B.K. PHARMA was founded on 01-03-2011.
Is B.K. PHARMA still active?
Yes, B.K. PHARMA is an active enterprise in the KBO register.
How many employees does B.K. PHARMA have?
B.K. PHARMA had an average of 1 full-time equivalents in financial year 2025, according to the filed annual accounts.Financials
What is the turnover of B.K. PHARMA?
The turnover in financial year 2025 is about €390,000. This figure is estimated from the gross margin of €112,702 and 37 comparable companies (NACE 477). It probably lies between €300,000 and €670,000.
Is B.K. PHARMA profitable?
In financial year 2025, B.K. PHARMA made a profit of €26,588.
Where can I find the annual accounts of B.K. PHARMA?
B.K. PHARMA filed 15 annual accounts with the National Bank of Belgium, the latest for financial year 2025.
When are the next annual accounts of B.K. PHARMA due?
B.K. PHARMA must file the annual accounts for financial year 2026 by 31-07-2027.Timeline

Next steps

See how customers, suppliers and banks see your own company and what to improve first.

Keep this company with today's facts in a case file.